Ado-trastuzumab Emtansine: Targeted Therapy for HER2 Breast Cancer

Summary of Key Points

Ado-trastuzumab emtansine is a targeted therapy used to treat HER2-positive breast cancer. It works by delivering chemotherapy directly to cancer cells, minimizing damage to healthy cells. This medication is typically prescribed when other treatments for breast cancer have not been successful. It’s crucial to follow your doctor’s instructions closely and report any side effects you experience. For personalized care, consider consulting one of our telemedicine providers.

Names of Medication

US Brand Name: Kadcyla

Generic Name: Ado-trastuzumab emtansine

The generic name, Ado-trastuzumab emtansine, refers to the active ingredient, while Kadcyla is the brand name given by the manufacturer.

Pharmacologic Category

Ado-trastuzumab emtansine belongs to the following pharmacologic categories:

1. Antineoplastic Agent
2. HER2 Inhibitor
3. Antibody-Drug Conjugate

Dosing Information

Ado-trastuzumab emtansine is used to treat various types of breast cancer, including HER2-positive breast cancer. The dosage and duration of treatment depend on your specific condition. Always consult your doctor before making any changes to your dose or treatment plan. You can also schedule a telemedicine appointment with one of our providers for further guidance.

Breast Cancer (HER2-positive, Metastatic, Locally Advanced, Invasive, Recurrent, Hormone Receptor-positive, Triple-negative, Stage IV)

Initial Dose: 3.6 mg/kg intravenously (IV) every 3 weeks

Frequency: Every 3 weeks (21-day cycle)

Length of Treatment: Continue until disease progression or unacceptable toxicity

Dosage Forms and Strengths

Ado-trastuzumab emtansine is available in the following dosage forms:

1. Lyophilized powder for injection: 100 mg per vial
2. Lyophilized powder for injection: 160 mg per vial

Administration Instructions

Ado-trastuzumab emtansine is administered as an intravenous (IV) infusion by a healthcare professional. The infusion typically lasts between 30 and 90 minutes. You will be monitored during and after the infusion for any side effects. It’s important not to miss any scheduled doses. If you do miss a dose, contact your healthcare provider immediately to reschedule. Do not attempt to administer this medication on your own.

Adverse Reactions and Side Effects

Like all medications, Ado-trastuzumab emtansine can cause side effects. Some are more common than others, and it’s important to report any unusual symptoms to your healthcare provider. If you experience severe side effects, seek medical attention immediately.

Common Side Effects:

1. Nausea: Feeling nauseous is common and can often be managed with anti-nausea medications.
2. Fatigue: Many patients experience unusual tiredness or weakness. Rest and staying hydrated may help alleviate this.
3. Headache: Mild to moderate headaches may occur.

Less Common Side Effects:

1. Thrombocytopenia: A decrease in platelets, which can increase the risk of bleeding or bruising.
2. Elevated Liver Enzymes: This may indicate liver irritation or damage. Your doctor may monitor your liver function through blood tests.

Serious Side Effects:

1. Heart Problems: Ado-trastuzumab emtansine can affect how well your heart pumps blood. Symptoms may include shortness of breath, swelling in the legs, or rapid weight gain.
2. Lung Problems: In rare cases, this medication can cause lung inflammation, leading to difficulty breathing or coughing.

Contraindications

A contraindication is a specific condition where a medication should not be used because it may cause harm. It’s important to know if you have any conditions that would make taking Ado-trastuzumab emtansine unsafe. Below are the main contraindications for Ado-trastuzumab emtansine:

1. Allergic Reaction to Ado-trastuzumab emtansine: If you’ve had a severe allergic reaction to this medication or any of its components, you should not take it. Allergic reactions can cause serious complications, including difficulty breathing and swelling.
2. Liver Disease: Ado-trastuzumab emtansine is processed by the liver. If you have severe liver disease, taking this medication could worsen your condition or lead to liver failure.
3. Pregnancy: Ado-trastuzumab emtansine can harm an unborn baby. It is contraindicated during pregnancy unless no other treatment options are available, as it can cause birth defects or even fetal death.

Drug-to-Drug Interactions

Some medications can interact with Ado-trastuzumab emtansine, potentially increasing side effects or reducing the treatment’s effectiveness. Inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements. Below are some known drug interactions:

1. Ketoconazole (Nizoral): This antifungal medication can increase Ado-trastuzumab emtansine levels in your body, leading to heightened side effects.
2. Rifampin (Rifadin): This antibiotic can reduce the effectiveness of Ado-trastuzumab emtansine by speeding up how quickly your body breaks it down.
3. Carbamazepine (Tegretol): This medication, used to treat seizures and nerve pain, can also reduce the effectiveness of Ado-trastuzumab emtansine.
4. Phenytoin (Dilantin): Another seizure medication that may lower Ado-trastuzumab emtansine levels in your body, making it less effective.

Ado-trastuzumab Emtansine in Pregnancy

Is it safe to take Ado-trastuzumab emtansine when pregnant?

No, Ado-trastuzumab emtansine is not considered safe during pregnancy. This targeted cancer therapy can harm a developing fetus, potentially leading to birth defects or even fetal death. If you are pregnant or planning to become pregnant, it’s essential to discuss alternative breast cancer treatments with your healthcare provider. Should you become pregnant while taking this medication, contact your healthcare provider immediately to discuss the next steps.

Ado-trastuzumab Emtansine While Breastfeeding

Is it safe to take Ado-trastuzumab emtansine while breastfeeding?

It is not recommended to take Ado-trastuzumab emtansine while breastfeeding. Although there is limited data on whether the drug passes into breast milk, the potential for serious side effects in a nursing infant remains a concern. Therefore, it’s advised to avoid breastfeeding while on this medication. Speak with your healthcare provider about whether you should stop breastfeeding or explore alternative treatments for HER2-positive breast cancer.

Estimated Cost of Ado-trastuzumab Emtansine

The cost of Ado-trastuzumab emtansine (Kadcyla) can vary depending on your location and pharmacy. Without insurance, the estimated cost for a 30-day supply using a GoodRX coupon ranges from approximately $10,000 to $12,000. Be sure to check with your pharmacy for the most accurate pricing, and explore financial assistance programs if needed to help manage the cost of this targeted cancer therapy.

Possible Alternatives to Ado-trastuzumab Emtansine

If Ado-trastuzumab emtansine is not suitable for you, there are other breast cancer treatment options available, depending on the type of cancer you have. Always discuss any changes to your treatment plan with your healthcare provider, or schedule a telemedicine appointment with one of our providers to explore your options.

Breast Cancer Treatment Alternatives

Alternatives may include surgery, radiation therapy, or other chemotherapy drugs such as paclitaxel (Taxol) or doxorubicin (Adriamycin). Additionally, lifestyle changes like maintaining a healthy diet and engaging in regular exercise can support your overall well-being during treatment.

HER2-Positive Breast Cancer Alternatives

For HER2-positive breast cancer, other targeted therapies like trastuzumab (Herceptin) or pertuzumab (Perjeta) may be considered. These medications also target the HER2 protein but may have different side effect profiles compared to Ado-trastuzumab emtansine.

Metastatic Breast Cancer Treatment Options

Treatment options for metastatic breast cancer may include hormonal therapy, immunotherapy, or other chemotherapy agents like capecitabine (Xeloda). Palliative care to manage symptoms is also an important part of treatment for advanced-stage cancer.

Locally Advanced Breast Cancer

For locally advanced breast cancer, surgery and radiation are often used in combination with chemotherapy. Neoadjuvant therapy (treatment before surgery) may also be an option to shrink the tumor before surgical removal.

Invasive Breast Cancer

Invasive breast cancer is commonly treated with surgery, radiation, and chemotherapy. Hormonal therapy may also be used if the cancer is hormone receptor-positive, as it helps block the hormones that fuel cancer growth.

Recurrent Breast Cancer

Treatment for recurrent breast cancer depends on where the cancer has returned. Options may include surgery, radiation, or systemic therapies like chemotherapy or targeted treatments such as Ado-trastuzumab emtansine or other HER2-targeted therapies.

Hormone Receptor-Positive Breast Cancer

For hormone receptor-positive breast cancer, hormonal therapies like tamoxifen or aromatase inhibitors (e.g., anastrozole) are often used. These medications work by blocking the hormones that promote cancer growth.

Triple-Negative Breast Cancer

Triple-negative breast cancer is typically treated with chemotherapy, but immunotherapy drugs like pembrolizumab (Keytruda) may also be considered as part of the treatment plan.

Stage IV Breast Cancer

For Stage IV breast cancer, treatment focuses on controlling the spread of cancer and improving quality of life. Options may include chemotherapy, targeted therapy, or radiation to manage symptoms and slow disease progression.

Recent Updates on Ado-trastuzumab Emtansine Research

Recent studies have shown promising results for Ado-trastuzumab emtansine in treating HER2-positive breast cancer. Research published in 2022 highlighted its effectiveness in reducing the risk of cancer recurrence in early-stage HER2-positive breast cancer patients. Additionally, ongoing clinical trials are exploring its use in combination with other therapies to improve outcomes for patients with metastatic breast cancer.

As research continues, new treatment protocols may emerge, offering more personalized and effective options for patients. Be sure to stay informed and discuss any new developments with your healthcare provider, or schedule a telemedicine consultation with one of our providers to learn more about the latest treatment options available to you.

James Kingsley

Learn More